PRIMIDONE
Clinical safety rating: avoid
Positive evidence of fetus risks but benefits may outweigh risks in some cases
Primidone is a barbiturate that enhances GABA-A receptor activity, increasing chloride ion conductance and neuronal inhibition. It also has active metabolites, phenobarbital and phenylethylmalonamide, which contribute to anticonvulsant effects.
| Metabolism | Primidone is metabolized primarily in the liver via CYP450 enzymes, mainly CYP2C9 and CYP2C19, to active metabolites phenobarbital and phenylethylmalonamide. |
| Excretion | Renal: approximately 40% unchanged, 30% as phenobarbital, 20% as phenylethylmalonamide (PEMA); fecal: <5% |
| Half-life | Primidone: 10-12 hours; phenobarbital metabolite: 48-120 hours; PEMA: 16-18 hours. Steady-state requires 4-7 days for primidone but up to 2-3 weeks for phenobarbital accumulation. |
| Protein binding | Primidone: 20-30% bound to albumin; phenobarbital: 45-50% bound to albumin. |
| Volume of Distribution | Primidone: 0.6-1.0 L/kg; distributes widely, crosses blood-brain barrier and placenta. |
| Bioavailability | Oral: 90-100% (immediate-release tablets); food slightly delays absorption but does not affect extent. |
| Onset of Action | Oral: 30-60 minutes for seizure protection; IV not available; parenteral routes not clinically used. |
| Duration of Action | Oral: 6-8 hours for primidone; accumulation of phenobarbital extends effective duration to 12-24 hours with repeated dosing. |
Initial: 100-125 mg orally at bedtime for 3 days; increase to 100-125 mg twice daily for 3 days, then 100-125 mg three times daily for 3 days; maintenance: 250 mg three times daily. Maximum: 500 mg four times daily.
| Dosage form | TABLET |
| Renal impairment | CrCl 30-49 mL/min: administer q8h. CrCl 10-29 mL/min: administer q12h. CrCl <10 mL/min: administer q24h. Dialyzable: yes; supplement 30% of dose post-hemodialysis. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 25-50%. Child-Pugh C: reduce dose by 50% or avoid use. |
| Pediatric use | Initial: 2-3 mg/kg/day divided q8h, increase over 2 weeks to 10-25 mg/kg/day divided q8h. Maximum: 1 g/day in 2-3 divided doses. |
| Geriatric use | Initiate at 100-125 mg/day; increase slowly (every 3-5 days) by 100-125 mg increments; monitor for sedation, ataxia, and cognitive impairment. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
CNS depressants may enhance sedative effects Can cause sedation and megaloblastic anemia.
| Breastfeeding | Primidone and its metabolites (phenobarbital, PEMA) are excreted into breast milk. M/P ratio for primidone is approximately 0.8; for phenobarbital, about 0.4-0.6. Infant serum levels can reach therapeutic or sedative ranges, potentially causing drowsiness, poor feeding, or withdrawal on weaning. Use caution; monitor infant for sedation and adequate weight gain. |
| Teratogenic Risk | Pregnancy Category D. First trimester: Increased risk of major malformations, particularly neural tube defects, cleft lip/palate, and cardiac anomalies, attributed to folic acid antagonism. Second/third trimester: Continued risk of growth restriction, dysmorphic features, and cognitive impairment. Neonatal hemorrhage due to vitamin K deficiency and withdrawal syndrome (hyperexcitability, seizures) may occur. |
■ FDA Black Box Warning
Primidone may be habit forming. Tolerance and psychological and physical dependence may occur with prolonged use. Withdrawal symptoms may occur following abrupt discontinuation and can be severe or fatal. Use with caution in patients with a history of drug or alcohol abuse.
| Common Effects | Sedation |
| Serious Effects |
Hypersensitivity to primidone, phenobarbital, or any component of the formulation. Porphyria. Concomitant use with other CNS depressants may potentiate effects; use with caution.
| Precautions | Risk of respiratory depression, particularly with high doses or when combined with other CNS depressants. Caution in patients with hepatic or renal impairment, porphyria, or history of substance abuse. Avoid abrupt withdrawal to prevent precipitating status epilepticus. |
Loading safety data…
| Fetal Monitoring | Preconception: Folic acid supplementation (4-5 mg/day) to reduce neural tube defect risk. During pregnancy: Serial ultrasound for fetal growth and anatomy; maternal serum alpha-fetoprotein (MSAFP) screening or amniocentesis for neural tube defects; assess vitamin K levels and administer phytomenadione to neonate at birth. Monitor maternal anticonvulsant levels (free primidone and phenobarbital) due to pregnancy-induced pharmacokinetic changes. |
| Fertility Effects | Primidone may affect fertility through enzyme induction, potentially altering sex hormone metabolism and menstrual cyclicity. Limited human data; animal studies show no significant direct impairment. Caution in women with preexisting reproductive disorders. |